Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-392-8412
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$38.42 million
Profitability
Miscellaneous
Employees141
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions
What is Sutro Biopharma's stock symbol?
Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."
How were Sutro Biopharma's earnings last quarter?
Sutro Biopharma Inc (NASDAQ:STRO) posted its earnings results on Wednesday, August, 14th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.05. The company earned $10.53 million during the quarter, compared to the consensus estimate of $8.38 million. View Sutro Biopharma's Earnings History.
When is Sutro Biopharma's next earnings date?
What price target have analysts set for STRO?
6 brokerages have issued 1-year target prices for Sutro Biopharma's shares. Their forecasts range from $16.00 to $23.00. On average, they anticipate Sutro Biopharma's share price to reach $20.20 in the next year. This suggests a possible upside of 88.8% from the stock's current price. View Analyst Price Targets for Sutro Biopharma.
What is the consensus analysts' recommendation for Sutro Biopharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sutro Biopharma.
What are Wall Street analysts saying about Sutro Biopharma stock?
Here are some recent quotes from research analysts about Sutro Biopharma stock:
- 1. According to Zacks Investment Research, "Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. " (8/17/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Sutro is derived from a 13-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.60, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.3%, and tax rate of 15% beginning in FY 2029. Until clarity on Sutro’s collaboration with Celgene and Merck crystallizes, our $18 price target remains leveraged on the outcome of STRO-002’s safety and efficacy outcome, which represents approximately 67% of our rNPV of $12 per share." (5/7/2019)
Has Sutro Biopharma been receiving favorable news coverage?
Media stories about STRO stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sutro Biopharma earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Sutro Biopharma.
Are investors shorting Sutro Biopharma?
Sutro Biopharma saw a increase in short interest in August. As of August 31st, there was short interest totalling 254,800 shares, an increase of 5.9% from the July 31st total of 240,500 shares. Based on an average daily volume of 48,700 shares, the days-to-cover ratio is presently 5.2 days. Currently, 2.9% of the company's shares are short sold. View Sutro Biopharma's Current Options Chain.
Who are some of Sutro Biopharma's key competitors?
Some companies that are related to Sutro Biopharma include BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), NanoString Technologies (NSTG), Vericel (VCEL), Mesoblast (MESO), Cortexyme (CRTX), AVITA MED LTD/S (AVMXY), GENFIT S A/ADR (GNFT), Voyager Therapeutics (VYGR), Osiris Therapeutics (OSIR), MeiraGTx (MGTX), DBV TECHNOLOGIE/S (DBVT) and Autolus Therapeutics (AUTL).
What other stocks do shareholders of Sutro Biopharma own?
Who are Sutro Biopharma's key executives?
Sutro Biopharma's management team includes the folowing people:
- Mr. William J. Newell, CEO & Director (Age 61)
- Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)
- Dr. Arturo M. Molina, Chief Medical Officer (Age 60)
- Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory Board
- Mr. Edward C. Albini, CFO & Sec. (Age 61)
When did Sutro Biopharma IPO?
(STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Sutro Biopharma's major shareholders?
Sutro Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.37%), Sio Capital Management LLC (1.48%), Point72 Asset Management L.P. (1.41%), Vanguard Group Inc. (0.85%), Jennison Associates LLC (0.69%) and Jennison Associates LLC (0.69%). Company insiders that own Sutro Biopharma stock include Daniel H Petree and Merck & Co, Inc. View Institutional Ownership Trends for Sutro Biopharma.
Which major investors are selling Sutro Biopharma stock?
STRO stock was sold by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, Pentwater Capital Management LP, SG Americas Securities LLC, Victory Capital Management Inc. and International Biotechnology Trust PLC. View Insider Buying and Selling for Sutro Biopharma.
Which major investors are buying Sutro Biopharma stock?
STRO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Creative Planning, Jennison Associates LLC, Jennison Associates LLC, Vanguard Group Inc., Bank of New York Mellon Corp and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Sutro Biopharma.
How do I buy shares of Sutro Biopharma?
Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sutro Biopharma's stock price today?
One share of STRO stock can currently be purchased for approximately $10.70.
How big of a company is Sutro Biopharma?
Sutro Biopharma has a market capitalization of $245.35 million and generates $38.42 million in revenue each year. The company earns $-35,320,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe.View Additional Information About Sutro Biopharma.
What is Sutro Biopharma's official website?
How can I contact Sutro Biopharma?
Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.
MarketBeat Community Rating for Sutro Biopharma (NASDAQ STRO)
MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote "Outperform" if you believe STRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
